Breaking News Instant updates and real-time market news.

AGN

Allergan

$227.55

-4.81 (-2.07%)

, VTAE

Vitae Pharmaceuticals

$20.99

0.02 (0.10%)

08:02
10/17/16
10/17
08:02
10/17/16
08:02

Allergan, Vitae Pharmaceuticals announce expiration of HSR waiting period

Allergan (AGN) and Vitae Pharmaceuticals (VTAE) announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in the fourth quarter.

AGN

Allergan

$227.55

-4.81 (-2.07%)

VTAE

Vitae Pharmaceuticals

$20.99

0.02 (0.10%)

  • 26

    Oct

  • 02

    Nov

  • 06

    Nov

AGN Allergan
$227.55

-4.81 (-2.07%)

09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $294
LEER
Outperform
Leerink positive on Allergan ahead of Restasis patent decision
Leerink analyst Jason Gerberry is positive on Allergan's franchise outlook as he believes the company will either maintain a double-digit top-line" growth pharma" trajectory or alternatively institute a dividend, and will prevail in the ongoing Restasis patent challenge. Gerberry likes Allergan's underlying growth trends of the gastro and derm franchises and pipeline optionality, and reiterates an Outperform rating and $294 price target on the shares.
VTAE Vitae Pharmaceuticals
$20.99

0.02 (0.10%)

09/15/16
BMOC
09/15/16
DOWNGRADE
BMOC
Market Perform
Vitae Pharmaceuticals downgraded to Market Perform at BMO Capital
Vitae Pharmaceuticals (VTAE) has agreed to be acquired by Allergan (AGN) for $21 per share in cash.
09/15/16
WELS
09/15/16
DOWNGRADE
WELS
Market Perform
Vitae downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Vitae Pharmaceuticals (VTAE) to Market Perform following the proposed acquisition of Allergan (AGN). The deal's valuation is "relatively cheap and leaves open some possibility of a competing bid and modest price bump," Birchenough tells investors in a research note. He lowered his price target range for the shares to $21-$27 from $27-$32.
09/15/16
JMPS
09/15/16
NO CHANGE
JMPS
Kadmon has positive read through from Allergan deal, says JMP Securities
JMP Securities analyst Michael King says that Allergan's (AGN) acquisition of Vitae Pharmaceuticals (VTAE) bodes well for Kadmon's (KDMN) ROCK inhibitor KD025 for patients with psoriasis. The analyst says that the main driver for the Vitae deal was its oral RORyt inhibitor VTP-43742 which could become a psoriasis treatment. There are "mechanistic similarities" between Vitae's drug and Kadmon's psoriasis drug candidate KD025, King wrote. He reiterates a $16 price target and Outperform rating on Kadmon.
09/20/16
PIPR
09/20/16
DOWNGRADE
PIPR
Neutral
Vitae Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff downgraded Vitae Pharmaceuticals (VTAE) to Neutral citing Allergan's (AGN) takeover of the company. The analyst does not expect other offers to emerge.

TODAY'S FREE FLY STORIES

TIF

Tiffany

$90.95

1.98 (2.23%)

13:05
09/19/17
09/19
13:05
09/19/17
13:05
Options
Tiffany call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

13:00
09/19/17
09/19
13:00
09/19/17
13:00
General news
FOMC forecast revisions »

FOMC forecast revisions…

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:58
09/19/17
09/19
12:58
09/19/17
12:58
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

KR

Kroger

$21.29

-0.1501 (-0.70%)

12:55
09/19/17
09/19
12:55
09/19/17
12:55
Options
Kroger put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 30

    Nov

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:51
09/19/17
09/19
12:51
09/19/17
12:51
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

FCAU

Fiat Chrysler

$17.10

0.275 (1.64%)

12:49
09/19/17
09/19
12:49
09/19/17
12:49
Hot Stocks
FCA US recalling 443,712 U.S.-market heavy-duty pickups, medium-duty trucks »

FCA US LLC is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$75.16

-0.15 (-0.20%)

12:48
09/19/17
09/19
12:48
09/19/17
12:48
Hot Stocks
Microsoft Azure IP Advantage available in China on October 1 »

Microsoft said on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

AA

Alcoa

$45.77

0.86 (1.91%)

12:45
09/19/17
09/19
12:45
09/19/17
12:45
Options
Alcoa call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$4.15

-0.25 (-5.68%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Conference/Events
Noodles & Company management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Schneiderman, coalition of AGs expand multistate probe into opioid crisis »

New York Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.48

-3.06 (-1.38%)

ABC

AmerisourceBergen

$80.24

-0.43 (-0.53%)

CAH

Cardinal Health

$66.37

-0.7 (-1.04%)

MCK

McKesson

$150.02

1.6 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Lexicon announces European Commission approves Xermelo »

Lexicon Pharmaceuticals…

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

12:35
09/19/17
09/19
12:35
09/19/17
12:35
General news
Today's U.S. reports »

Today's U.S. reports…

LEG

Leggett & Platt

$45.25

-0.635 (-1.38%)

12:34
09/19/17
09/19
12:34
09/19/17
12:34
Conference/Events
Leggett & Platt management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, VIA

Viacom

$37.45

-0.4 (-1.06%)

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Periodicals
Viacom leak may have compromised digital properties, Gizmodo reports »

A security researcher…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

VIA

Viacom

$37.45

-0.4 (-1.06%)

VIAB

Viacom

$27.32

-0.35 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACTG

Acacia Research

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Hot Stocks
Acacia Research shares trade higher amid insider buying »

A number of insiders at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$48.82

0.79 (1.64%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Conference/Events
Green Dot management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$155.77

1.28 (0.83%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Options
Adobe attracts a pre-earnings call writer »

Adobe attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

12:28
09/19/17
09/19
12:28
09/19/17
12:28
Hot Stocks
Michigan AG says 41 state attorneys general now involved in opioid probe »

Michigan Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.49

-3.05 (-1.38%)

ABC

AmerisourceBergen

$80.20

-0.47 (-0.58%)

CAH

Cardinal Health

$66.36

-0.71 (-1.06%)

MCK

McKesson

$149.89

1.47 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

EFX

Equifax

$94.55

0.17 (0.18%)

12:27
09/19/17
09/19
12:27
09/19/17
12:27
Periodicals
Massachusetts Attorney General files lawsuit against Equifax, Reuters reports »

The State of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ADK

AdCare

$0.98

-0.01 (-1.01%)

12:26
09/19/17
09/19
12:26
09/19/17
12:26
Conference/Events
AdCare to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDIT

Editas Medicine

$21.37

0.43 (2.05%)

12:26
09/19/17
09/19
12:26
09/19/17
12:26
Conference/Events
Editas Medicine management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBRY

BlackBerry

$9.26

-0.01 (-0.11%)

12:25
09/19/17
09/19
12:25
09/19/17
12:25
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

CARB

Carbonite

$21.70

1.2 (5.85%)

12:25
09/19/17
09/19
12:25
09/19/17
12:25
Conference/Events
Carbonite to hold financial analyst and investor day »

Financial Analyst and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

12:25
09/19/17
09/19
12:25
09/19/17
12:25
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DWDP

DowDuPont

$69.92

0.15 (0.21%)

12:22
09/19/17
09/19
12:22
09/19/17
12:22
Conference/Events
DowDuPont management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.